Details for New Drug Application (NDA): 021191
✉ Email this page to a colleague
NDA 021191 describes IMAGENT, which is a drug marketed by Vesselon Spv Llc and Alliance Pharm and is included in two NDAs. Additional details are available on the IMAGENT profile page.
The generic ingredient in IMAGENT is perflubron. Additional details are available on the perflubron profile page.
The generic ingredient in IMAGENT is perflubron. Additional details are available on the perflubron profile page.
Summary for 021191
| Tradename: | IMAGENT |
| Applicant: | Vesselon Spv Llc |
| Ingredient: | dimyristoyl lecithin; perflexane |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INTRAVENOUS | Strength | 0.92MG/VIAL;0.092MG/VIAL | ||||
| Approval Date: | May 31, 2002 | TE: | RLD: | No | |||||
Expired US Patents for NDA 021191
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Vesselon Spv Llc | IMAGENT | dimyristoyl lecithin; perflexane | INJECTABLE;INTRAVENOUS | 021191-001 | May 31, 2002 | 6,280,704 | ⤷ Subscribe |
| Vesselon Spv Llc | IMAGENT | dimyristoyl lecithin; perflexane | INJECTABLE;INTRAVENOUS | 021191-001 | May 31, 2002 | 5,605,673 | ⤷ Subscribe |
| Vesselon Spv Llc | IMAGENT | dimyristoyl lecithin; perflexane | INJECTABLE;INTRAVENOUS | 021191-001 | May 31, 2002 | 5,798,091 | ⤷ Subscribe |
| Vesselon Spv Llc | IMAGENT | dimyristoyl lecithin; perflexane | INJECTABLE;INTRAVENOUS | 021191-001 | May 31, 2002 | 6,280,705 | ⤷ Subscribe |
| Vesselon Spv Llc | IMAGENT | dimyristoyl lecithin; perflexane | INJECTABLE;INTRAVENOUS | 021191-001 | May 31, 2002 | 5,720,938 | ⤷ Subscribe |
| Vesselon Spv Llc | IMAGENT | dimyristoyl lecithin; perflexane | INJECTABLE;INTRAVENOUS | 021191-001 | May 31, 2002 | 6,287,539 | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
